SCHEMBL1879284

SCHEMBL1879284

CC(=O)O[C@@H]1CCCC[C@H]1Oc1ccc(Br)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPY1R P25929 1/20 0.41
NPY2R P49146 1/20 0.41
NPY4R P50391 1/20 0.41
NPY5R Q15761 1/20 0.41
SLC18A3 Q16572 2/20 0.41
MAOB P27338 1/20 0.38
ALOX5 P09917 1/20 0.38
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
CHRNA7 P36544 1/20 0.36
POLB P06746 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1879285 1.00 ALDH1A1 (0.43) ALDH1A1MEN1KMT2ANPY1RNPY2R
SCHEMBL11503010 0.79 MMP13 (0.45) ALDH1A1SLC18A3MAPTMAPK1RAB9A
SCHEMBL11510907 0.79 LSS (0.54) ALDH1A1MEN1KMT2AMAOBLMNA
SCHEMBL1875896 0.77 PTGS1 (0.39) MEN1SLC18A3ALOX5IDO1TDO2
SCHEMBL1875894 0.77 PTGS1 (0.39) MEN1SLC18A3ALOX5IDO1TDO2
SCHEMBL7920287 0.75 CHRM2 (0.48) MEN1KMT2ASLC18A3NPSR1
SCHEMBL7926060 0.75 CHRM2 (0.48) MEN1KMT2ASLC18A3NPSR1
SCHEMBL7926056 0.75 CHRM2 (0.48) MEN1KMT2ASLC18A3NPSR1
SCHEMBL4607042 0.75 GRIA4 (0.43) MEN1KMT2ASLC18A3MAOB
SCHEMBL1878371 0.75 ENPP3 (0.40) ALDH1A1MEN1KMT2ANPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051917-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF BIOGEN MA INC (US) 2024-02-15 US disclosed
US-20190100491-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER INC. 2019-04-04 US disclosed
US-20170247360-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF BIOGEN MA INC. 2017-08-31 US disclosed
US-20160272625-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER INC. (US) 2016-09-22 US disclosed
US-20140323502-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF BIOGEN MA INC. 2014-10-30 US disclosed
EP-2445883-B1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER (US) 2014-08-13 EP disclosed
US-20120322823-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER INC. 2012-12-20 US disclosed
US-8278457-B2 Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof PFIZER INC. (US) 2012-10-02 US disclosed
EP-2445883-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF Pfizer Inc. (US) 2012-05-02 EP disclosed
US-20110105533-A1 Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof PFIZER INC. 2011-05-05 US disclosed
WO-2010150192-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105533-A1 Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof STS, SULT2A1, SULT1A1 ALDH1A1 382/4885MEN1 1536/4885KMT2A 1144/4885
US-20240051917-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF STS, SULT2A1, SULT1A1 ALDH1A1 382/4885MEN1 1536/4885KMT2A 1144/4885
US-20120322823-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF STS, SULT2A1, SULT1A1 ALDH1A1 382/4885MEN1 1536/4885KMT2A 1144/4885
US-20140323502-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF STS, SULT2A1, SULT1A1 ALDH1A1 382/4885MEN1 1536/4885KMT2A 1144/4885
US-20160272625-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF STS, SULT2A1, SULT1A1 ALDH1A1 382/4885MEN1 1536/4885KMT2A 1144/4885
US-20170247360-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF STS, SULT2A1, SULT1A1 ALDH1A1 382/4885MEN1 1536/4885KMT2A 1144/4885
US-20190100491-A1 HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF STS, SULT2A1, SULT1A1 ALDH1A1 382/4885MEN1 1536/4885KMT2A 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.